VAY736

Status
Phase 2
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Subcutaneous (SC) Injection
Funder Type
Industry

Drug Details

VAY736 (ianalumab) is a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody.

Study Purpose

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Find a Clinical Trial
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >